Eva Meluzínová

1.6k total citations
29 papers, 601 citations indexed

About

Eva Meluzínová is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Eva Meluzínová has authored 29 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in Eva Meluzínová's work include Multiple Sclerosis Research Studies (19 papers), Polyomavirus and related diseases (5 papers) and Immunotherapy and Immune Responses (3 papers). Eva Meluzínová is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), Polyomavirus and related diseases (5 papers) and Immunotherapy and Immune Responses (3 papers). Eva Meluzínová collaborates with scholars based in Czechia, United States and Switzerland. Eva Meluzínová's co-authors include Eva Havrdová, Klaus Schmierer, Ludwig Kappos, Mefkûre Eraksoy, Tarek Yousry, David MacManus, Ralf Gold, Volker Limmroth, Chris H. Polman and Gilmore O’Neill and has published in prestigious journals such as The Lancet, PLoS ONE and Journal of the American Academy of Dermatology.

In The Last Decade

Eva Meluzínová

19 papers receiving 580 citations

Peers

Countries citing papers authored by Eva Meluzínová

Since Specialization

Citations

This map shows the geographic impact of Eva Meluzínová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Meluzínová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Meluzínová more than expected).

Fields of papers citing papers by Eva Meluzínová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Meluzínová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Meluzínová. The network helps show where Eva Meluzínová may publish in the future.

Co-authorship network of co-authors of Eva Meluzínová

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Meluzínová. A scholar is included among the top collaborators of Eva Meluzínová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Meluzínová. Eva Meluzínová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis 2022 ·PLoS ONE ·(unknown), Eva Meluzínová, (unknown), (unknown), (unknown), (unknown), Martin Elišák, (unknown), (unknown), Ondřej Sobek, Petr Marusič	12
2	Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry 2022 ·Frontiers in Neurology ·Martin Vališ, (unknown), Michal Novotný, Blanka Klímová, (unknown), (unknown), (unknown), Ivana Štětkářová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Marta Vachová, (unknown), Eva Meluzínová	3
3	Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic 2021 ·Multiple Sclerosis and Related Disorders ·Pavel Hradílek, Eva Meluzínová, Olga Zapletalová, (unknown), Dana Horáková, (unknown), (unknown), Ivana Štětkářová, (unknown), Pavel Štourač, (unknown), Radek Ampapa, Marta Vachová, Jan Mareš	4
4	Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease? 2020 ·Journal of Neurology ·(unknown), Adam Kalina, Tomáš Nikolai, Martin Vyhnálek, Eva Meluzínová, Jan Laczó	8
5	Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease? 2020 ·Journal of Neurology ·(unknown), Adam Kalina, Tomáš Nikolai, Martin Vyhnálek, Eva Meluzínová, Jan Laczó	0
6	Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients 2020 ·Česká a slovenská neurologie a neurochirurgie ·(unknown), Eva Meluzínová, (unknown), (unknown), (unknown), (unknown), Martin Elišák, (unknown)	0
7	Health-related quality of life, neuropsychiatric symptoms and structural brain changes in clinically isolated syndrome 2018 ·PLoS ONE ·(unknown), Adam Kalina, Martin Vyhnálek, Tomáš Nikolai, (unknown), Jiří Lisý, Jakub Hort, Eva Meluzínová, Jan Laczó	12
8	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ 2017 ·PLoS ONE ·(unknown), Eva Meluzínová, Aleš Tomek, Dana Horáková, Ivana Kovářová, Václav Maťoška, (unknown), (unknown), (unknown), Petra Lišková, (unknown), (unknown), Martin Bojar, Eva Havrdová, Petr Marusič	1
9	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program 2017 ·Therapeutics and Clinical Risk Management ·Eva Havrdová, Jeffrey Cohen, Dana Horáková, Ivana Kovářová, Eva Meluzínová	22
10	Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis 2016 ·Journal of Neurology ·(unknown), Martin Vyhnálek, Adam Kalina, (unknown), Tomáš Nikolai, Jiří Lisý, Jakub Hort, Eva Meluzínová, Jan Laczó	33
11	Alemtuzumab v léčbě roztroušené sklerózy 2015 ·Neurologie pro praxi ·Eva Meluzínová	0
12	Kvalita života pacientů s roztroušenou sklerózou mozkomíšní 2014 ·Neurologie pro praxi ·(unknown), Eva Meluzínová, (unknown)	0
13	Dimethyl-fumarát v léčbě relabující-remitující formy roztroušené sklerózy 2014 ·Eva Meluzínová, Martin Bortlík	0
14	Management of psoriasis vulgaris and multiple sclerosis with fumaric acid 2014 ·Journal of the American Academy of Dermatology ·Spyridon Gkalpakiotis, Petr Arenberger, (unknown), Eva Meluzínová, (unknown), Monika Arenbergerová	5
15	Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study 2011 ·Multiple Sclerosis Journal ·Ludwig Kappos, Ralf Gold, David H. Miller, David MacManus, Eva Havrdová, Volker Limmroth, Chris H. Polman, Klaus Schmierer, Tarek Yousry, Mefkûre Eraksoy, Eva Meluzínová, Michal Dufek, Minhua Yang, K. P. DAWSON, Gilmore O’Neill	54
16	BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis 2010 ·Journal of Neurology ·David MacManus, D. H. Miller, Ludwig Kappos, Ralf Gold, Eva Havrdová, Volker Limmroth, Chris H. Polman, Klaus Schmierer, Tarek Yousry, Mefkûre Eraksoy, Eva Meluzínová, Michal Dufek, (unknown), Gilmore O’Neill, (unknown)	37
17	The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions 2008 ·UCL Discovery (University College London) ·David MacManus, D L Miller, Ludwig Kappos, Richard H. Gold, Eva Havrdová, (unknown), C.H. Polman, Klaus Schmierer, Tarek Yousry, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, (unknown), Kevin J. Dawson	2
18	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study 2008 ·The Lancet ·Ludwig Kappos, Ralf Gold, David H. Miller, David MacManus, Eva Havrdová, Volker Limmroth, Chris H. Polman, Klaus Schmierer, Tarek Yousry, Minhua Yang, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, Katherine Dawson, Alfred Sandrock, Gilmore O’Neill	375
19	Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study 2006 ·UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, (unknown), (unknown), Klaus Schmierer, Tarek Yousry, Meixiao Long, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, (unknown)	13
20	BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis 2006 ·UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, (unknown), CH Polman, Klaus Schmierer, (unknown), Min Yang, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact